Vedanta Biosciences

Executive Summary

Vedanta Biosciences is a clinical-stage biotechnology company developing defined bacterial consortia as live biotherapeutic products (LBPs) to treat serious gastrointestinal diseases. Founded in 2010 and headquartered in Cambridge, Massachusetts, the company leverages a proprietary platform to rationally design oral therapies that correct gut dysbiosis, a key driver of inflammatory and infectious conditions. Vedanta's lead candidate, VE202, is a rationally defined bacterial consortium targeting inflammatory bowel disease (IBD) and has shown promising results in Phase 2 trials. The company is also advancing a pipeline for recurrent C. difficile infection and other GI indications, positioning itself at the forefront of the microbiome therapeutics field. With a strong intellectual property portfolio and strategic partnerships, Vedanta aims to address the unmet medical need for safe and effective microbiome-based treatments.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 top-line data readout for VE202 in ulcerative colitis50% success
• Q1 2027Initiation of Phase 3 trial for VE202 in C. difficile infection60% success
• Q4 2026Strategic partnership or licensing deal for one of the pipeline programs40% success